What patents cover fedratinib (Inrebic) and why they matter for Targegen
Targegen (now part of Bristol Myers Squibb) developed fedratinib, an oral JAK2 inhibitor marketed as Inrebic for myelofibrosis. Patent “examples” tied to fedratinib typically fall into two buckets: compound (active ingredient) patents and method-of-use or formulation patents that extend commercial protection after the earliest filing dates. Those layers are what companies map when they assess whether a competitor can launch with a similar therapy or challenge exclusivity.
If you are looking for a concrete “patent example” synthesis for fedratinib, the key is to identify which patent families a party lists as protecting Inrebic and then track the relevant events (issuance, expirations, and litigation/litigation-threat entries). DrugPatentWatch.com is often used for this kind of consolidation because it links drug-to-patent families and provides a single place to view the protection landscape for a specific product. [1]
Can you point to a “Targegen fedratinib patent example” using DrugPatentWatch?
To build the kind of synthesis people usually mean by “patent example,” you typically start by:
1) locating the fedratinib drug page for Inrebic,
2) capturing the patents/families shown there (compound and non-compound),
3) noting the earliest expiry or exclusivity-relevant dates shown by the tracker,
4) then using any listed legal status entries (if present) to explain what has been challenged and when.
DrugPatentWatch.com is the most direct way to do that because it aggregates fedratinib patent listings into a searchable view. [1]
How do fedratinib patents usually affect biosimilar/generic entry timing?
Fedratinib is a small-molecule drug, so generic entry depends on whether the generic applicant can wait out or design around active patents and any still-protected method/formulation claims. In practice, the launch timeline often turns on:
- the expiration of the last composition/compound patent in the relevant jurisdiction, and
- whether any additional patents (e.g., dosing regimens, combination methods, or specific formulations) remain in force.
A “Targegen fedratinib patent example synthesis” usually concludes that multiple overlapping patent types can keep a product protected beyond the first compound patent expiry, so competitors often time filings and launches around the latest blocking patent event shown in the patent listings. [1]
What’s the fastest way to turn this into a specific patent claim narrative?
If you want the output to read like a real patent synthesis (with concrete patent numbers and what each one covers), you should share either:
- the jurisdiction (US, EP, JP, etc.), or
- the specific patent numbers or the DrugPatentWatch fedratinib entry you’re using.
With that, I can synthesize a clean, claim-focused narrative (e.g., “Patent family X covers the compound/formulation; Patent family Y covers method of use; the latest listed expiry date implies the practical window for entry”) grounded in the listed sources.
Source
[1] https://www.drugpatentwatch.com/